Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: An in vitro study

British Journal of Cancer

Volumn 92, Issue 2, 2005, Pages 350-358

  Mukherjee, A ^a   Westwell, A D ^a   Bradshaw, T D ^a   Stevens, M F G ^a   Carmichael, J ^a   Martin, S G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Chemotherapy; Colorectal cancer and antiangiogenesis; Hypoxia; Thioredoxin

Indexed keywords

ANTINEOPLASTIC AGENT; AW 464; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; NSC 706704; PROTEIN INHIBITOR; THIOREDOXIN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CELL DIFFERENTIATION; CELL HYPOXIA; CELL LINE; CELL PROLIFERATION; CELL STRAIN HT29; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG SENSITIVITY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; IC 50; INTERMETHOD COMPARISON; KERATINOCYTE; PRIORITY JOURNAL;

ANOXIA; ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; BREAST NEOPLASMS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLOHEXANONES; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; THIAZOLES;

EID: 14844293843     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602338     Document Type: Article

References (54)

1. Anema SM, Walker SW, Howie AF, Arthur JR, Nicol F, Beckett GJ (1999) Thioredoxin reductase is the major selenoprotein expressed in human umbilical-vein endothelial cells and is regulated by protein kinase C. Biochem J 342: 111-117
2. Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J, Powis G (1996) Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res 16: 3459-3466
3. Berlin JD (2002) Targeting vascular endothelial growth factor in colorectal cancer. Oncology (Huntingt) 16(Supplement): 13-15
4. Bocci G, Nicolaou KC, Kerbel RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62: 6938-6943
5. Bossi P, Viale G, Lee KAC, Alfano RM, Coggi G, Bosari S (1995) Angiogenesis in colorectal tumours: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res 55: 5049-5053
6. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886
7. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium based semi-automated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942
8. Chun YS, Kim MS, Park JW (2002) Oxygen-dependent and -independent regulation of HIF-lalpha. J Korean Med Sci 17: 581-588
9. Dicker AP, Williams T, Grant DS (2001) Targeting angiogenic processes by combination of Rofecoxib and ionising radiation. Am J Clin Oncol (CCT) 24: 438-442
10. Don AS, Kisker O, Dilda P, Donoghue N, Zhao X, Decollogne S, Creighton B, Flynn E, Folkman J, Hogg PJ (2003) A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 3: 497-509
11. Drevs J (2003) Soluble markers for the detection of hypoxia under antiangiogenic treatment. Anticancer Res 23: 1159-1161
12. Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K, Poellinger L, Kuriyama Y (1999) Molecular mechanisms of transcription activation by HLF and HIF1α in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 18: 1905-1914
13. Fernando MR, Nanri H, Yoshitake S, Nagata-Kuno K, Minakami S (1992) Thioredoxin regenerates proteins inactivated by oxidative stress in endothelial cells. Eur J Biochem 209: 917-922
14. Folkman J (1990) What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 82: 4-6
15. Frank RE, Saclarides TJ, Leurgans S, Speziale NJ, Drab EA, Rubin DB (1995) Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 222: 695-699
16. Freshney RI (1994) Culture of Animal Cells: A Manual of Basic Technique 3rd edn. New York: Wiley-Liss, pp 200-201
17. Gately S, Kerbel R (2001) Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 7: 427-436
18. Harmey JH, Bouchier-Hayes D (2002) Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for antiangiogenic therapy. Bioessays 24: 280-283
19. Hirano S, Cui X, Li S, Kanno S, Kobayashi Y, Hayakawa T, Shraim A (2003) Difference in uptake and toxicity of trivalent and pentavalent inorganic arsenic in rat heart microvessel endothelial cells. Arch Toxicol 77: 305-312
20. Hirota K, Nakamura H, Masutani H, Yodoi J (2002) Thioredoxin superfamily and thioredoxin-inducing agents. Ann NY Acad Sci 957: 189-199
21. Ishibashi H, Shiratuchi T, Nakagawa K, Onimaru M, Sugiura T, Sueishi K, Shirasuna K (2001) Hypoxia-induced angiogenesis of cultured human salivary gland carcinoma cells enhances vascular endothelial growth factor production and basic fibroblast growth factor release. Oral Oncol 37: 77-83
22. Jaffe EA, Nachman RL, Becker CG, Minick CR (1973) Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest 52: 2745-2756
23. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/ LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65
24. Kahlos K, Soini Y, Sauf M, Koistinen P, Kakko S, Paakko P, Holmgren A, Kinnula VL (2001) Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int J Cancer 95: 198-204
25. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, Sivridis E, Georgoulias V, Gatter KC, Harris AL (2001) Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 7: 3087-3091
26. Le YJ, Corry PM (1999) Hypoxia-induced bFGF gene expression is mediated through the JNK signal transduction pathway. Mol Cell Biochem 202: 1-8
27. Lechner S, Muller-Ladner U, Schlottmann K, Jung B, McClelland M, Ruschoff J, Welsh J, Scholmerich J, Kullmann F (2002) Bile acids mimic oxidative stress induced upregulation of thioredoxin reductase in colon cancer cell lines. Carcinogenesis 23: 1281-1288
28. Lee JC, Chow NH, Wang ST, Huang SM (2000) Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36: 748-753
29. Lichtenfels R, Kellner R, Atkins D, Bukur J, Ackermann A, Beck J, Brenner W, Melchior S, Seliger B (2003) Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim Biophys Acta 1646: 21-31
30. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB (1993) Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 68: 1104-1109
31. Mau BL, Powis G (1992) Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin. Relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity. Biochem Pharmacol 43: 1621-1627
32. Meuillet EJ, Mahadevan D, Berggren M, Coon A, Powis G (2004) Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch Biochem Biophys 429: 123-133
33. Miyazaki K, Noda N, Okada S, Hagiwara Y, Miyata M, Sakurabayashi I, Yamaguchi N, Sugimura T, Terada M, Wakasugi H (1998) Elevated serum level of thioredoxin in patients with hepatocellular carcinoma. Biotherapy 11: 277-288
34. Pallis M, Bradshaw TD, Westwell AD, Grundy M, Stevens MF, Russell N (2003) Induction of apoptosis without redox catastrophe by thioredoxin- inhibitory compounds. Biochem Pharmacol 66: 1695-1705
35. Pantalone D, Ziehe M, Messerini L, Pazzagli M, Morbidelli L, Parenti A, Donnini S, Palomba AR, Tricarico C, Paolucci R, Taruffi F, Andreoli F (1999) An angiogenesis study of Dukes' B colonic tumors. Clin Terapeut 150: 331-337
36. Ponce ML (2001) In vitro Matrigel angiogenesis assays. In Methods in Molecular Medicine, 46 Angiogenesis Protocols Murray JC (ed) pp 205-209. Humana Press Inc.: Totowa, NJ
37. Powis G, Kirkpatrick DL, Angulo M, Baker A (1998) Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chem Biol Interactions 111-112: 23-34
38. Powis G, Montfort WR (2001) Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct 30: 421-455
39. Powis G, Welsh SJ, Kirkpatrick LD (2003) HIF1 as a cancer drug target: its inhibition and anti-tumour activity by PX-478. Programmes and Proceedings of the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics. p 254
40. Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, Alberts DS, Powis G (2003) Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 142: 46-51
41. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, Ichijo H (1998) Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596-2606
42. Saunders DE, Lawrence WD, Christensen C, Wappler NL, Ruan H, Deppe G (1997) Paclitaxel-induced apoptosis in MCF-7 breast cancer cells. Int J Cancer 70: 214-220
43. Schallreuter KU, Wood JM (2001) Thioredoxin reductase - its role in epidermal redox status. J Photochem Photobiol B 64: 179-184
44. Shao L, Diccianni MB, Tanaka T, Gribi R, Yu AL, Pullen JD, Camitta BM, Yu J (2001) Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication. Cancer Res 61: 7333-7338
45. Sullivan DC, Huminiecki L, Moore JW, Boyle JJ, Poulsom R, Creamer D, Barker J, Bicknell R (2003) EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor. J Biol Chem 278: 47079-47088
46. Wells G, Berry JM, Bradshaw TD, Burger AM, Seaton A, Wang B, Westwell AD, Stevens MF (2003) 4-Substituted 4-hydroxycyclohexa-2,5-dien-1-ones with selective activities against colon and renal cancer cell lines. J Med Chem 46: 532-541
47. Welsh SJ, Bellamy WT, Briehl MM, Powis G (2002) The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1α protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62: 5089-5095
48. Welsh SJ, Williams R, Berggren M, Kirkpatrick DL, Powis G (2003b) The anti-tumor activity of PX-478 an inhibitor of hypoxia-inducible factor-1α (HIF-1α) is associated with decreased HIF-1α and plasma VEGF. Proceedings of the American Association for Cancer Research 94th Annual Meeting (2003), vol 44, p 1063 (abstract 4634)
49. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G (2003a) The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1α and vascular endothelial growth factor formation. Mol Cancer Ther 2: 235-243
50. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G (2004) Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α. Mol Cancer Ther 3: 233-244
51. Westwell AD, Berry JM, Bradshaw TD, Chew EH, Matthews CS, Monks A, Schwalbe CH, Stevens MF (2003) Phenolic oxidation products as novel antitumour agents. Programmes and Proceedings of the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, vol 186, no. C6
52. Xie K, Wei D, Shi Q, Huang S (2004) Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev 15: 297-324
53. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000) Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545
54. Zhou J, Schmid T, Frank R, Brune B (2004) PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1α from pVHL-independent degradation. J Biol Chem 279: 13506-13513